Market Cap 542.42B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.51
Forward PE 19.94
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 8,040,900
Avg Vol 7,792,926
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 7%
Beta 0.27
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
OnlyFibs
OnlyFibs Jun. 2 at 3:36 AM
$JNJ trading ~$223.51, showing aggressive institutional positioning as shown in "image_ab5278.png" with significant call blocks targeting the $230$250 range through August. 📈 Setup: Smart money is betting on a summer recovery, with heavy block buying in the $230 calls (07/17) and $250 calls (08/21), indicating institutional confidence in the oncology pipeline. 🐂 Bull Trigger: A clean daily close above $230.00 confirms the institutional breakout, setting the stage for a push toward $240.00 and beyond. 🐻 Bear Level: A failure to hold $220.00 support invalidates the bullish flow and risks a deeper retest of the $215.00 zone. 📊 Trend: BULLISH — Unusual option activity shows clear accumulation at these levels, betting on a reversal driven by pipeline execution. #jnj #optionsflow #hovdid
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jun. 1 at 6:53 PM
$JNJ 225. Eod or eow!?
0 · Reply
pilobious
pilobious Jun. 1 at 4:55 PM
$JNJ very weak the last few days. Looking for news.
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 4:10 PM
$BCTX Announced positive clinical data from three clinical data poster presentations at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jun. 1 at 3:59 PM
$JNJ bounce would be great. anytime now.
0 · Reply
theoptionsplug
theoptionsplug Jun. 1 at 2:16 PM
Watch $JNJ for a double bottom bounce here!
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 1:58 PM
CANCER STOCK NEWS: $BCTX delivers at ASCO 2026 ✅ 55% 1-year survival ✅27% 2-year survival ✅Heavily pre-treated metastatic breast cancer This is the kind of dataset that can re-rate a biotech. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 1 at 1:19 PM
$IBRX $JNJ $MRK $NVAX $XBI Time to show!
0 · Reply
clan
clan Jun. 1 at 12:15 PM
$GSK Great news for diabetic kiddos!!! FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 $ABBV $JNJ $MRK
0 · Reply
PickAlpha
PickAlpha Jun. 1 at 11:58 AM
Morning Report | Oil risk premium jumps, AI-chip controls tighten $NVDA China licensing enforcement tightens · $ARM SoftBank signals €75bn France buildout · $NVDA Windows PCs, humanoid robotics push · $SMMT ASCO spotlights PD-(L)1/VEGF data · $JNJ Perioperative Erleada catalyst in prostate https://open.substack.com/pub/pickalpha/p/morning-report-oil-risk-premium-jumps?r=1m2m41&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
0 · Reply
Latest News on JNJ
Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 12 days ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 27 days ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 4 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 4 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 5 weeks ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: AGM 2026


Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 6 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system


Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026


Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings release: Q1 2026


Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Slides: Q1 2026


Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Quarterly report: Q1 2026


J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 6 weeks ago

J&J raises guidance for 2026 on strong start to the year


Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook


J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 6 weeks ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength


Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 2 months ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX


OnlyFibs
OnlyFibs Jun. 2 at 3:36 AM
$JNJ trading ~$223.51, showing aggressive institutional positioning as shown in "image_ab5278.png" with significant call blocks targeting the $230$250 range through August. 📈 Setup: Smart money is betting on a summer recovery, with heavy block buying in the $230 calls (07/17) and $250 calls (08/21), indicating institutional confidence in the oncology pipeline. 🐂 Bull Trigger: A clean daily close above $230.00 confirms the institutional breakout, setting the stage for a push toward $240.00 and beyond. 🐻 Bear Level: A failure to hold $220.00 support invalidates the bullish flow and risks a deeper retest of the $215.00 zone. 📊 Trend: BULLISH — Unusual option activity shows clear accumulation at these levels, betting on a reversal driven by pipeline execution. #jnj #optionsflow #hovdid
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jun. 1 at 6:53 PM
$JNJ 225. Eod or eow!?
0 · Reply
pilobious
pilobious Jun. 1 at 4:55 PM
$JNJ very weak the last few days. Looking for news.
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 4:10 PM
$BCTX Announced positive clinical data from three clinical data poster presentations at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jun. 1 at 3:59 PM
$JNJ bounce would be great. anytime now.
0 · Reply
theoptionsplug
theoptionsplug Jun. 1 at 2:16 PM
Watch $JNJ for a double bottom bounce here!
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 1:58 PM
CANCER STOCK NEWS: $BCTX delivers at ASCO 2026 ✅ 55% 1-year survival ✅27% 2-year survival ✅Heavily pre-treated metastatic breast cancer This is the kind of dataset that can re-rate a biotech. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 1 at 1:19 PM
$IBRX $JNJ $MRK $NVAX $XBI Time to show!
0 · Reply
clan
clan Jun. 1 at 12:15 PM
$GSK Great news for diabetic kiddos!!! FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 $ABBV $JNJ $MRK
0 · Reply
PickAlpha
PickAlpha Jun. 1 at 11:58 AM
Morning Report | Oil risk premium jumps, AI-chip controls tighten $NVDA China licensing enforcement tightens · $ARM SoftBank signals €75bn France buildout · $NVDA Windows PCs, humanoid robotics push · $SMMT ASCO spotlights PD-(L)1/VEGF data · $JNJ Perioperative Erleada catalyst in prostate https://open.substack.com/pub/pickalpha/p/morning-report-oil-risk-premium-jumps?r=1m2m41&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Jun. 1 at 10:45 AM
$NVDA $AMD $HYPE $JNJ A blockbuster geopolitical guidance was issued on Sunday, one that could potentially impact Nvidia and AMD going forward. https://www.earlybird.email/p/nvidia-amd-face-new-china-export-limits-as-u-s-closes-chip-loophole
0 · Reply
SenefAS
SenefAS Jun. 1 at 9:07 AM
$GMAB buy now or cry later 🙃 -> -Truist assumes Genmab coverage with a Buy rating on pipeline - Highlights company's three lead assets with up to seven key readouts expected in 2026 -Sets $40 target $XBI $IBB $JNJ
0 · Reply
maikl_211
maikl_211 Jun. 1 at 4:24 AM
0 · Reply
inspector_gadget86
inspector_gadget86 May. 31 at 7:02 PM
$CMPS $DJT $LLY $JNJ The push brings both opportunities and risks for patients and the companies developing the therapies.
1 · Reply
focafoca99
focafoca99 May. 31 at 6:40 PM
$JNJ posted Phase 3 PROTEUS results showing apalutamide plus hormone therapy reduces metastasis risk by 20% in high‑risk prostate cancer. https://www.rapidticker.com/news/jnj-johnson-johnsons-phase-3-prostate-9668ba
0 · Reply
KostasBars
KostasBars May. 31 at 4:27 PM
$JNJ https://news.sky.com/story/striking-cancer-jabs-destroys-tumours-in-treatment-resistant-cases-in-trial-13549483
0 · Reply
focafoca99
focafoca99 May. 31 at 4:10 PM
$JNJ shows strong durable responses in advanced head and neck cancer, with a 42% overall response rate and over one‑third complete responses https://www.rapidticker.com/news/jnj-rybrevant-faspro-amivantamab-and-hyaluronidase-81151d
0 · Reply
BioRich
BioRich May. 31 at 3:25 PM
$SLS is an absolute disgrace this sham of a company is even mentioned in the same breath as $SMMT $RVMD $JNJ or $IBRX. If you care about the science and not the pump and dump, you'd be better suited in one of these vs. Hype stock $SLS that only tested 10 subjects for AML CR2, 10 years ago, by another company. Congrats to the real oncology companies creating real life changing treatments for the patients that so desperately deserve it. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how find these gems and learn. Let's make some (more) money. Cheers!
ElliottwaveForecast
ElliottwaveForecast May. 31 at 10:10 AM
📊 Johnson & Johnson – Elliott Wave Rally Elliott Wave analysis signals $JNJ is advancing toward the 259 level, with the bullish cycle unfolding as expected. The structure highlights continued upside momentum as long as price holds above recent pivots. 🎯 The rally toward 259 marks the next key target in the bullish sequence. Pullbacks are expected to remain supported, keeping $JNJ aligned with the upward path. Read the full analysis 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-signals-rally-toward-259/ #ElliottWave #Trading #Stocks
0 · Reply
HuhereChapter11
HuhereChapter11 May. 30 at 9:36 PM
$SLS Wen $JNJ ?
0 · Reply
FarrUkk
FarrUkk May. 30 at 5:37 PM
$JNJ Amivantamab🧐
0 · Reply
betaloop
betaloop May. 30 at 5:29 PM
$JNJ positive lung cancer treatment tests
0 · Reply